HighTide Therapeutics, Inc. disclosed an updated list of directors and detailed the latest committee assignments, effective 4 May 2026.

The Board comprises nine members: two executive directors (Chairwoman and CEO Dr. Liu Liping, and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong, and Mr. Jiang Feng), and three independent non-executive directors (Dr. Li Jin, Mr. Hung Tak Wai, and Mr. Chen Mingyu).

Committee structure and leadership are as follows: • Audit Committee – chaired by Mr. Chen Mingyu, with Dr. Li Jin and Mr. Hung Tak Wai serving as members. • Remuneration Committee – chaired by Dr. Li Jin, with Mr. Chen Mingyu as a member. • Nomination Committee – chaired by Dr. Liu Liping, with Dr. Li Jin and Mr. Hung Tak Wai as members.

The announcement underscores the company’s adherence to corporate governance best practices through a clear separation of roles and a majority of independent non-executive directors on each committee.